产品
编 号：F626431
分子式：C18H14N4O
分子量：302.33
分子式：C18H14N4O
分子量：302.33
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1190277-80-5
产品详情
生物活性：
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.
体内研究：
MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice.Animal Model:Five-week-old female BALB/c nude mice (BT549 cells).
Dosage:50 mg/kg.
Administration:Twice per week by intraperitoneal (i.p.) injection.
Result:Reduced tumor growth.
体外研究：
MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells.MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells.MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation.MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells.
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer.
体内研究：
MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice.Animal Model:Five-week-old female BALB/c nude mice (BT549 cells).
Dosage:50 mg/kg.
Administration:Twice per week by intraperitoneal (i.p.) injection.
Result:Reduced tumor growth.
体外研究：
MKI-1 (5-20 μM) inhibits the activity of MASTL in breast cancer cells.MKI-1 (100 μM, 72 h) inhibits various oncogenic properties of breast cancer cells but showed much weaker effects on the viability of normal breast cells.MKI-1 clearly reduces both serine 62-phosphorylation of c-Myc and total c-Myc, with a decrease in ENSA phosphorylation.MKI-1 (20 μM, 16 h) reduces c-Myc stability through PP2A activation in MCF7 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备